Related Experiment Video
Updated: May 28, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Association of menopause and hormone replacement therapy with large artery remodeling
Anne Gompel1, Pierre Boutouyrie, Robinson Joannides
1Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Hôtel-Dieu, Paris, France. anne.gompel@htd.aphp.fr
Objective:
To evaluate the remodeling of large arteries according to age at menopause, duration of menopause, and use of hormone therapy (HT).
Design:
A cross-sectional study consisting of baseline measurements of a multicentric randomized trial were used to evaluate arterial parameters.
Setting:
The study was conducted in France, Belgium, and the Netherlands in academic hospitals and private clinics.
Patient(S):
Postmenopausal women (n = 538) with mild hypercholesterolemia.
Intervention(S):
None.
Main Outcome Measure(S):
Common carotid artery intima-media thickness (CCA-IMT), central pulse pressure, and aortic stiffness (carotid-femoral pulse wave velocity) were measured and centrally controlled for quality. Multivariate regression analysis was used to assess the possible covariates associated with arterial parameters.
Result(S):
Women were 58 ± 6 (mean ± SD) years of age with an age of 50 ± 5 at menopause and a mean duration of menopause of 8 ± 7 years. Lower age at menopause, time since menopause, and absence of HT use were independently associated with worsening of the arterial parameters. After multivariate analysis, HT was associated with a lower CCA-IMT (-40 μm [range -64 to -1]), whereas lower age at menopause and menopause duration were respectively associated with a CCA-IMT increase (25 μm/5 y and 27 μm/5 y). Similarly, values of central pulse pressure and pulse wave velocity were lower in HT users (-3.1 mm Hg [-5.1 to -0.9] and -0.31 m/s [-0.63 to -0.02], respectively) but worsened with age at menopause and menopause duration.
Conclusion(S):
The age at menopause, the time since menopause, and the use of HT are independently associated with the thickening and stiffening of the large arteries.
Clinical Trial Registration Number:
NCT00163163.
Related Concept Videos
Bone Remodeling
Aortic Regurgitation III: Medical Management
Atherosclerosis III: Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Menopause
Coronary Artery Disease I: Introduction